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Aim and scope
The European Renal Best Practice (ERBP) Advisory Board
recently decided to follow up existing guidelines, and to
publish position statements when new evidence would ne-
cessitate a change in the existing guideline [1].The purpose
of this document is to provide guidance on the interpretation
and relevancy of the current European Best Practice Guide-
line (EBPG) on dialysis strategy [2], in the light of the re-
cently published Membrane Permeability Outcome (MPO)
study [3].This position statement is intended to be consid-
ered in conjunction with the current guideline. It does not
replace the guideline as we do not include a new systematic
reviewof the literature. TheMPO study specifically focused
on the question whether the use of a high-, compared to a
low-flux dialyser membrane, would have a measurable ef-
fect on survival.
Current guideline
The current European guideline relating to dialyser mem-
brane permeability or flux is contained in the EBPG guide-
line on dialysis strategies [2], published in 2007.
This document contains the following recommendation:
Guideline 2.1: The use of synthetic high-flux membranes
should be considered to delay long-term complications of
haemodialysis therapy. Specific indications include: to
reduce dialysis-related amyloidosis (level III); to improve
control of hyperphosphataemia (level II); to reduce the
increased cardiovascular risk (level II); to improve con-
trol of anaemia (level III).
At the time the guideline was prepared, there was insuffi-
cient evidence available to linkmembrane permeability with
survival. This lack of evidence is reflected in the wording of
the guideline, which mentions only relatively soft or surro-
gate outcomes such as anaemia, hyperphosphataemia, etc.
The evidence for improved phosphate control is controver-
sial. Thewording ‘should be considered’, is, in effect, a level
II (weak) recommendation. The evidence regarding the out-
comes are moderate or weak (levels II or III) according to
the grading system used in the guideline.
The guideline cites the Hemodialysis (HEMO) study [4]
as the only randomized clinical trial (RCT) available which
addressed the influence of high-flux dialysis on survival di-
rectly. This study found no difference in survival between
high- and low-flux in the study group as a whole. However,
post hoc, subgroup analysis suggested that high-flux dialy-
sis decreased cardiac death in the entire cohort and de-
creased all-cause mortality in patients who had been on
long-term dialysis. This subgroup analysis was considered
to be suggestive of possible benefit, but insufficient on itself
to make the recommendation in the guideline more strongly.
The MPO study
There is now a second RCT available, the MPO study [2],
published in December 2008.
The MPO study compared survival in 647 patients ran-
domized between high and low flux, and who completed
the study. The study was designed to have increased sen-
sitivity to the influence of treatment, compared to the
HEMO study, by selecting patients with relatively greater
mortality risk. This was achieved by studying incident pa-
tients with a serum albumin ≤40 g/l [2]. The HEMO study
enrolled prevalent patients, who had been on dialysis for
an average of 3.7 years, effectively being a group of select-
ed survivors, a large part of whom had been treated by
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high flux before. By enrolling only incident patients, the
MPO study, thus, also avoided confounding or hangover
effects related to the membrane type used prior to the start
of the study. Numerous studies have shown that low serum
albumin is associated with multiple adverse factors (e.g.
malnutrition, inflammation, vascular disease) as well as in-
creased mortality risk.
The MPO study found no significant difference in sur-
vival between high- and low-flux groups when all patients
were included in the analysis. However, when considering
only patients with serum albumin ≤40 g/l on enrolment,
there was a significant 37% reduction in mortality risk in
patients treated by high flux. Post hoc subgroup analysis
demonstrated significantly improved survival in patients
with diabetes when treated by high flux. There was a sig-
nificant improvement (reduction in the rate of increase) in
serum beta-2-microglobulin levels in patients treated by
high-, compared to low-flux membranes for the whole
group.
Interpretation and evidence level
The MPO study was designed to test the hypothesis that
high flux improved outcome in patients with low serum
albumin. Patients with normal serum albumin were added
as a separate group in order to increase numbers while the
study was underway. The normal and low albumin groups
were separately randomized [5].
The MPO study provides level A (high grade) evidence
that survival is improved by use of high-flux membranes in
high-risk patients as identified by serum albumin ≤40 g/l.
The evidence level is also A for the effect of flux on serum
beta-2-microglobulin. The MPO study provides level B or
C (moderate or low grade) evidence that high flux im-
proves survival in diabetics as this is a secondary subgroup
analysis. The MPO study did not provide evidence for high
flux improving survival in other groups of patients or in
the group as a whole.
In clinical practice, preference of low vs high flux can be
based on financial restraints, and the need of ultrapure wa-
ter when using high flux. As assuring water quality is a
centre-specific item, and high flux should be commended
in patients at risk based on high-grade evidence, the only
factor hampering the use of high flux in all patients is the
small difference in cost between a high- and a low-flux fil-
ter in a limited group of patients. As such, it makes sense
to recommend using high flux in all patients, even if the
evidence to support the use of high flux in patients with
low risk is lacking.
Guidance and conclusion
The MPO study does not undermine the current guidance
which suggests preferential use of high-flux membranes in
all patients. The ERBP Advisory Board considers that the
MPO study provides sufficient evidence to upgrade the
strength of the guidance to a level 1A (strong recommen-
dation, based on high-quality evidence) that high-flux di-
alysis should be used in the case of high-risk patients
(comparable to the low-albumin group of the MPO study).
In view of the small incremental extra cost of high-flux fil-
ters, the high prevalence of albumin <40 g/l at start of di-
alysis, and the substantial improvement in an intermediate
marker (beta-2-microglobulin) in the high-flux group of
the MPO study, the ERBP Advisory Board considers that
expanding the use of high flux to all patients makes sense.
The recommendation to use high flux in all patients re-
mains at 2B (weak recommendation, based on moderate
quality evidence).
The existing Guideline 2.1 should thus be replaced by
the following:
Guideline 2.1: Synthetic high-flux membranes should
be used to delay long-term complications of haemodia-
lysis therapy in patients at high risk (serum albumin
<40 g/l) (level 1A: strong recommendation, based on
high-quality evidence). In view of underlying practical
considerations, and the observation of a reduction of an
intermediate marker (beta-2-microglobulin), synthetic
high-flux membranes should be recommended even in
low-risk patients (level 2B: weak recommendation, low
quality evidence).
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